The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Measuring subjective improvement as well as objective response to estimate the benefit of palliative chemotherapy in women with platinum-resistant or -refractory ovarian cancer: The symptom benefit study (ANZGOG-0701/GCIG/PoCoG).
M. Friedlander
No relevant relationships to disclose
M. R. Stockler
No relevant relationships to disclose
M. King
No relevant relationships to disclose
A. M. Oza
No relevant relationships to disclose
M. Voysey
No relevant relationships to disclose
J. Martyn
No relevant relationships to disclose
K. Gillies
No relevant relationships to disclose
K. M. Sjoquist
No relevant relationships to disclose
P. Butow
No relevant relationships to disclose